PI-RADS classification: Structured reporting for MRI of the prostate;PI-RADS-Klassifikation: Strukturiertes Befundungsschema für die MRT der Prostata

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 185, Issue 3, 2013, Pages 253-261

  Rothke M ^a   Blondin, D ^b   Schlemmer, H P ^a   Franiel, T ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

MR diffusion perfusion; MR imaging; MR spectroscopy; prostate

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIODIAGNOSIS;

BIOPSY; CONSENSUS; COOPERATIVE BEHAVIOR; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; GUIDELINE ADHERENCE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INTERDISCIPLINARY COMMUNICATION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; QUALITY ASSURANCE, HEALTH CARE;

EID: 84874480285     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0032-1330270     Document Type: Article

References (52)

1. Schlemmer H. P. Multiparametric MRI of the prostate: method for early detection of prostate cancer? Fortschr Röntgenstr: 2010; 182 1067 1075 10.1055/s-0029-1245786
2. Franiel T. Multiparametric magnetic resonance imaging of the prostate - technique and clinical applications. Fortschr Röntgenstr: 2011; 183 607 617 10.1055/s-0029-1246055
3. Barentsz J. O., Richenberg J., Clements R. et al. ESUR prostate MR guidelines 2012. Eur Radiol: 2012; 22 746 757 10.1007/s00330-011-2377-y
4. Dickinson L., Ahmed H. U., Allen C. et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. European urology: 2011; 59 477 494 10.1016/j.eururo.2010.12.009
5. Krebsgesellschaft D. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. 2011
6. Wagner M., Rief M., Busch J. et al. Effect of butylscopolamine on image quality in MRI of the prostate. Clin Radiol: 2010; 65 460 464 S0009-9260(10)00106-6
7. Roethke M. C., Lichy M. P., Jurgschat L. et al. Tumorsize dependent detection rate of endorectal MRI of prostate cancer - a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer. Eur J Radiol: 2011; 79 189 195 S0720-048X(10)00045-8
8. Akin O., Sala E., Moskowitz C. S. et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology: 2006; 239 784 792 2392050949 (Pubitemid 43830614)
9. Janus C., Lippert M. Benign prostatic hyperplasia: appearance on magnetic resonance imaging. Urology: 1992; 40 539 541 (Pubitemid 23003202)
10. Oto A., Kayhan A., Jiang Y. et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology: 2010; 257 715 723 radiol.1010002
11. Wang L., Mazaheri Y., Zhang J. et al. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology: 2008; 246 168 176 2461070057 (Pubitemid 350305040)
12. Hricak H. Imaging prostate cancer. J Urol: 1999; 162 1329 1330
13. Kim C. K., Park B. K., Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr: 2006; 30 7 11 00004728-200601000-00002 [pii] (Pubitemid 43052291)
14. Beyersdorff D., Taymoorian K., Knosel T. et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. Am J Roentgenol: 2005; 185 1214 1220 185/5/1214 [pii]10.2214/Am J Roentgenol.04.1584
15. Roethke M. C., Lichy M. P., Kniess M. et al. Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol: 2012; 10.1007/s00345-012-0826-0
16. Zelhof B., Pickles M., Liney G. et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int: 2009; 103 883 888
17. Sato C., Naganawa S., Nakamura T. et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging: 2005; 21 258 262 10.1002/jmri.20251 (Pubitemid 40280120)
18. Mulkern R. V., Barnes A. S., Haker S. J. et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging: 2006; 24 563 568 (Pubitemid 43776563)
19. Quentin M., Blondin D., Klasen J. et al. Comparison of different mathematical models of diffusion-weighted prostate MR imaging. Magnetic resonance imaging: 2012; 10.1016/j.mri.2012.04.025
20. Le Bihan D., Breton E., Lallemand D. et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology: 1988; 168 497 505
21. Yablonskiy D. A., Bretthorst G. L., Ackerman J. JH. Statistical model for diffusion attenuated MR signal. Magn Reson Med: 2003; 50 664 669 (Pubitemid 37187828)
22. Jensen J. H., Helpern J. A., Ramani A. et al. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med: 2005; 53 1432 1440 (Pubitemid 40734665)
23. Haider M. A., van der Kwast T. H., Tanguay J. et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol: 2007; 189 323 328 (Pubitemid 47195916)
24. Pickles M. D., Gibbs P., Sreenivas M. et al. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging: 2006; 23 130 134 (Pubitemid 43191065)
25. Ren J., Huan Y., Wang H. et al. Diffusion-weighted imaging in normal prostate and differential diagnosis of prostate diseases. Abdom Imaging: 2008; 33 724 728
26. Kim C. K., Park B. K., Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. Am J Roentgenol: 2010; 194 33 37 194/1/W33
27. Mueller-Lisse U. G., Mueller-Lisse U. L., Zamecnik P. et al. Diffusion-weighted MRI of the prostate. Radiologe: 2011; 51 205 214
28. Katahira K., Takahara T., Kwee T. C. et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol: 2011; 21 188 196
29. 2). J Magn Reson Imaging: 2012; 10.1002/jmri.23627
30. Woodfield C. A., Tung G. A., Grand D. J. et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol: 2010; 194 316 322
31. Vargas H. A., Akin O., Franiel T. et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology: 2011; 259 775 784 10.1148/radiol.11102066
32. Franiel T., Hamm B., Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol: 2011; 21 616 626 10.1007/s00330-010-2037-7
33. Huisman H. J., Engelbrecht M. R., Barentsz J. O. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging: 2001; 13 607 614 (Pubitemid 32231516)
34. Tofts P. S., Brix G., Buckley D. L. et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging: 1999; 10 223 232 (Pubitemid 29463104)
35. Beyersdorff D., Ludemann L., Dietz E. et al. Dynamic contrast-enhanced MRI of the prostate: comparison of two different post-processing algorithms. Fortschr Röntgenstr: 2011; 183 456 461 10.1055/s-0029-1246051
36. Franiel T., Stephan C., Erbersdobler A. et al. Areas Suspicious for Prostate Cancer: MR-guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding - Multiparametric MR Imaging for Detection and Biopsy Planning. Radiology: 2011; radiol.10101251
37. Ocak I., Bernardo M., Metzger G. et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol: 2007; 189 849
38. Sciarra A., Panebianco V., Ciccariello M. et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res: 2010; 16 1875 1883
39. Engelbrecht M. R., Huisman H. J., Laheij R. J. et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology: 2003; 229 248 254 (Pubitemid 37152132)
40. Padhani A. R., Gapinski C. J., Macvicar D. A. et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol: 2000; 55 99 109 (Pubitemid 32054531)
41. Schlemmer H. P., Merkle J., Grobholz R. et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol: 2004; 14 309 317 (Pubitemid 38181089)
42. Franiel T., Lüdemann L., Rudolph B. et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol: 2008; 43 481 487
43. Franiel T., Lüdemann L., Taupitz M. et al. Pharmacokinetic MRI of the Prostate: Parameters for Differentiating Low-Grade and High-Grade Prostate Cancer. Fortschr Röntgenstr: 2009; 181 536 542
44. Shukla-Dave A., Hricak H., Ishill N. M. et al. Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. Radiology: 2009; 250 803 812
45. Mueller-Lisse U. G., Swanson M. G., Vigneron D. B. et al. Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. Eur Radiol: 2007; 17 371 378 (Pubitemid 46140308)
46. Fradet V., Kurhanewicz J., Cowan J. E. et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology: 2010; 256 176 183 radiol.10091147
47. Verma S., Rajesh A., Futterer J. J. et al. Prostate MRI and 3D MR spectroscopy: how we do it. Am J Roentgenol: 2010; 194 1414 1426
48. Hoeks C. MA, Barentsz J. O., Hambrock T. et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology: 2011; 261 46 66
49. Scheenen T. WJ, Futterer J., Weiland E. et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol: 2011; 46 25 33
50. Weinreb J. C., Blume J. D., Coakley F. V. et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy - results of ACRIN prospective multi-institutional clinicopathologic study. Radiology: 2009; 251 122 133 251/1/122
51. Futterer J. J., Scheenen T. WJ, Heijmink S. WTPJ et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol: 2007; 42 116 122 (Pubitemid 46104892)
52. Jung J. A., Coakley F. V., Vigneron D. B. et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology: 2004; 233 701 708